$56.32
1.77% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$56.32
+11.05 24.41% 1M
+15.94 39.48% 6M
+17.72 45.91% YTD
+22.35 65.79% 1Y
+40.14 248.08% 5Y
+44.62 381.37% 10Y
+44.62 381.37% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.98 1.77%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Market capitalization $3.49b
Enterprise Value $2.92b
P/E (TTM) P/E ratio 63.28
EV/FCF (TTM) EV/FCF 8.70
EV/Sales (TTM) EV/Sales 14.03
P/S ratio (TTM) P/S ratio 16.80
P/B ratio (TTM) P/B ratio 5.06
Revenue growth (TTM) Revenue growth -34.02%
Revenue (TTM) Revenue $207.80m
EBIT (operating result TTM) EBIT $27.22m
Free Cash Flow (TTM) Free Cash Flow $335.29m
Cash position $574.36m
EPS (TTM) EPS $0.89
P/E forward negative
P/S forward 45.34
EV/Sales forward 37.88
Short interest 10.08%
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
208 208
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
1% 1%
19%
- Research and Development Expense 140 140
11% 11%
68%
31 31
79% 79%
15%
- Depreciation and Amortization 3.47 3.47
261% 261%
2%
EBIT (Operating Income) EBIT 27 27
82% 82%
13%
Net Profit 56 56
65% 65%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Business Wire
12 days ago
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a...
Neutral
Accesswire
23 days ago
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
Accesswire
about one month ago
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) p...
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today